Amarin Corporation plc (AMRN) P/E Ratio History
Historical price-to-earnings valuation from 2011 to 2021
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of February 28, 2026, Amarin Corporation plc (AMRN) trades at a price-to-earnings ratio of -3.5x, with a stock price of $13.80 and trailing twelve-month earnings per share of $-4.15.
The current P/E is 103% below its 5-year average of 117.4x. Over the past five years, AMRN's P/E has ranged from a low of 3.1x to a high of 522.7x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, AMRN trades at a 115% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, AMRN trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our AMRN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Commercial Specialty Pharma peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
UTHRUnited Therapeutics Corporation | $22B | 18.1Lowest | 0.94Best | +13% |
ALKSAlkermes plc | $5B | 21.0 | - | -34% |
ADMAADMA Biologics, Inc. | $4B | 19.2 | - | +723%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $67.40 | $0.46 | 147.3x | +25% |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $87.60 | $0.17 | 522.7x | +345% |
| FY2012 Q1 | Sat Mar 31 2012 00:00:00 GM | $226.40 | $33.62 | 6.7x | -94% |
| FY2011 Q4 | Sat Dec 31 2011 00:00:00 GM | $149.80 | $49.00 | 3.1x | -97% |
| FY2011 Q3 | Fri Sep 30 2011 00:00:00 GM | $184.00 | $21.61 | 8.5x | -93% |
| FY2011 Q2 | $288.60 | $17.61 | 16.4x | -86% |
Average P/E for displayed period: 117.4x
See AMRN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AMRN Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare AMRN vs AGIO
See how AMRN stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is AMRN stock overvalued or undervalued?
AMRN trades at -3.5x P/E, below its 5-year average of 117.4x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does AMRN's valuation compare to peers?
Amarin Corporation plc P/E of -3.5x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is AMRN's PEG ratio?
AMRN PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2011-2021.